NEWS HIGHLIGHTSMedia Articles Related to Levitra (Vardenafil)
Brief Amnesia After Taking Levitra?
Source: MedicineNet vardenafil Specialty [2008.06.02]
Title: Brief Amnesia After Taking Levitra?
Category: Health News
Created: 6/2/2008
Last Editorial Review: 6/2/2008
Tadalafil (Cialis) In The Treatment Of Erectile Dysfunction
Source: Erectile Dysfunction / Premature Ejaculation News From Medical News Today [2009.05.30]
UroToday.com - This updated review of tadalafil (Cialis), one of the three available phosphodiesterase type 5 (PDE5) inhibitors that revolutionized the treatment of erectile dysfunction (ED), analyzes its latest clinical studies. Tadalafil's most unique and identifying characteristic is its long half-life of 17.5 hours, compared with 4 hours for sildenafil (Viagra) and vardenafil (Levitra).
Vardenafil: A Potential Drug To Protect Gastric Mucosa
Source: Health News from Medical News Today [2009.11.19]
Indomethacin has been proved by epidemiological and experimental studies to be closely associated with peptic ulcer development. Vardenafil is a potent phosphodiesterase 5 inhibitor and its effects on the gastric mucosa have not been reported. A research article published in the World Journal of Gastroenterology addresses this problem. The research team, led by Dr.
Published Studies Related to Levitra (Vardenafil)
Vardenafil allows successful intercourse initiated rapidly after dosing in Japanese patients with diabetes mellitus and erectile dysfunction. [2009.10]
INTRODUCTION: Vardenafil is reported to improve success rates in the maintenance of an erection sufficient for completion of intercourse (SEP-3) compared with placebo in erectile dysfunction (ED) patients who attempted intercourse from as early as 15 minutes after dosing. However, these data were based on general ED patients, using time from administration to initiation of intercourse. It is unclear whether the results can be applied to difficult-to-treat ED patients, such as those with diabetes mellitus (DM), with the time between dosing and insertion into vagina. AIM: To determine whether early onset of activity with vardenafil is also achievable in ED patients with DM... CONCLUSIONS: In this retrospective analysis, a rapid onset of activity was also demonstrated in difficult-to-treat ED patients. Vardenafil improved successful intercourse rates compared with placebo in Japanese DM patients who inserted from as early as 15 minutes to >120 minutes after dosing.
Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. [2009.07]
Premature ejaculation (PE) is thought to be the most common male sexual dysfunction; however, the prevalence of lifelong (LL)-PE is relatively low. The aim of this study was to investigate the effects of on-demand vardenafil (10 mg) to modify the intravaginal ejaculatory latency time (IELT) in men with LL-PE without erectile dysfunction...
Safety and efficacy of vardenafil versus sertraline in the treatment of premature ejaculation: a randomised, prospective and crossover study. [2009.06]
We investigated safety and efficacy of vardenafil and sertraline in premature ejaculation (PE). Seventy-two men graded their primary PE on a scale of 0-8 (0 = almost never, 8 = almost always)...
Evaluation of vardenafil for the treatment of subjective tinnitus: a controlled pilot study. [2009.02.17]
BACKGROUND: Vardenafil (Levitra(R)) represents a potent and highly selective phosphodiesterase type 5 (PDE5) inhibitor, which is established for treatment of various diseases. There are several unpublished reports from patients stating that vardenafil has a considerable therapeutic effect on their concomitant tinnitus. This pilot study was conducted to specifically assess the effect of vardenafil in patients with chronic tinnitus... CONCLUSION: Although hypoxia and ischemia play a special role in the pathogenesis of tinnitus, the PDE5-inhibitor-induced increase of nitric oxide-mediated vasodilatation exerted no specific influence on tinnitus symptomatology. Considering the unclear risk of rarely associated hearing impairment, systemic application of vardenafil or other PDE5 inhibitors prove to be not appropriate for therapy of chronic tinnitus.
Does on-demand vardenafil improve erectile function recovery after radical prostatectomy? [2009.01]
The randomized, placebo-controlled trial reported by Montorsi and colleagues attempted to determine if nightly vardenafil was more effective than on-demand drug in restoring erectile function after radical prostatectomy. No significant difference in outcomes was found between the study groups at 11 or 13 months after surgery...
Clinical Trials Related to Levitra (Vardenafil)
ELATED: Evaluation of LEVITRA to Advance the Treatment of Erectile Dysfunction [Completed]
This is a multicentre, cluster-randomized, open-label flexible dose study with a 2x2
factorial design with administration of vardenafil at a dose of 5, 10 and 20 mg doses in
males with erectile dysfunction.
The treatment period is for 12 weeks, after a 4 week unmedicated period for subjects taking
ED medication. For ED treatment-naïve subjects (ie, previously not treated with ED
medication), the unmedicated period can be only 2 weeks.
Approximately 150 investigational centres may be utilised with approximately 10 subjects
screened and entered into a 4 week treatment free period at Visit 1 to subsequently enroll
approximately 1380 subjects to therapy. Each centre should enroll 10 subjects. Sites should
try to recruit approximately 50% of subjects who have not previously tried oral PDE5
inhibitor therapy for erectile dysfunction. An attempt should be made to enroll subjects
whose partners are interested in being involved.
Sites will be randomized in a 1: 1:1: 1 ratio to receive either the education intervention at
the Primary care Physician (PCP) level, at the subject level, both levels or no intervention
(usual care).
The PCP education program is an accredited CME program and included a comprehensive overview
on the screening and diagnosis of ED, the available treatment options and appropriate
treatment selection, as well as subject and partner counseling. The subject education was a
two-pronged approach which included physician-to-subject instruction and a direct-to-subject
education method.
After the unmedicated period, treatment was initiated with vardenafil 10 mg tablets for 4
weeks. This will be followed by a flexible dose titration period of 4 weeks during which
subjects may maintain the previous dosage regimen or will step up to 20 mg of vardenafil or
will step down to 5 mg vardenafil. There is a final 4 week treatment period where the
previous dosage regimen is either maintained, increased or decreased by one step according to
the three applicable dosage strengths of vardenafil (5, 10 or 20 mg). The highest applicable
dosage regimen of 20 mg vardenafil will not be exceeded. A 24 hour follow-up phone call is
required within 24 hours of the last dose of vardenafil to collect data concerning serious
adverse events, if needed.
REALISE Levitra® - Real Life Safety and Efficacy of Levitra [Completed]
Collect data on safety, efficacy, and subject acceptance of vardenafil treatment under daily
life conditions in a large number of subjects with erectile dysfunction (ED)
A Double-Blind "Preferred" Vardenafil Dose Study of QoL and Functional Outcomes in Males With Erectile Dysfunction [Completed]
To find out more information on how treating impotence with vardenafil in comparison to
placebo affects the quality of life (QoL) of men and their partners. Subjects will receive
10mg vardenafil or placebo for 4 weeks followed by an 8 week period when the dose of
vardenafil may be reduced to 5mg or increased to 20mg. Subjects will then receive their
'preferred' dose for 14 weeks. During this time Quality of Life Measures will be collected
via questionnaires
Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-Sparing Prostatectomy for Improving ED [Active, not recruiting]
To Investigate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction [Completed]
A total of 173 subjects were randomized in 6 centers (vardenafil: 129 subjects; placebo: 44
subjects). All 173 randomized subjects were analyzed for safety. Of these, 162 subjects
(94%) were included in the ITT sample (vardenafil: 123 subjects; placebo: 39 subjects) and
149 subjects (86%) were included in the PP sample (vardenafil: 115 subjects; placebo: 34
subjects). The PP sample was only used to analyze the primary efficacy variable (EF domain
score).
|
